Bernd Hirsch - Evotec AG Insider

EVOTF -- USA Stock  

USD 19.65  2.17  12.41%

Member of the Supervisory Board
Mr. Bernd Hirsch is Vice Chairman of the Supervisory Board at Evotec AG since June 9, 2015. Previously he was Member of the Supervisory Board at Evotec AG from June 2014. He is Chairman of the Audit Committee and Member of the Remuneration and Nomination Committee at the Company. He completed his degree in business administration at JuliusMaximiliansUniversitaet Wuerzburg and afterwards gained experience in various positions in the financial area. From 1998 to 2001, he was Audit Manager at the audit firm Arthur Andersen. In 2001, he started at Carl Zeiss Group as Head of Mergers Acquisitions. One year later, Mr. Hirsch was appointed Chief Financial Officer and Member of the Executive Board at Carl Zeiss Meditec AG. From December 2009 to December 2015, he was Chief Financial Officer and member of the Executive Board of Symrise AG. From April 1, 2016 onwards, Mr. Hirsch was Chief Financial Officer of Bertelsmann SE Co. KGaA. Furthermore, he acts as Director of Bertelsmann Inc., Penguin Random House LLC, Penguin Random House Limited and RTL Group S.A. Apart from his role as member of the Supervisory Board of Evotec AG, he does not hold memberships in any other comparable supervisory bodies.
Age: 46  Executive Since 2015      
49 40 5 60 81 0

Management Efficiency

The company has return on total asset (ROA) of 4.3 % which means that it generated profit of $4.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 6.24 % meaning that it generated $6.24 on every $100 dollars invested by stockholders.
The company has accumulated 212.96 M in total debt with debt to equity ratio (D/E) of 53.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.72 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 2178 people.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 2,178 people.

Evotec AG Leadership Team

Werner Lanthaler, CEO
Claus Braestrup, Executive
Michael Shalmi, Executive, MBA
Mario Polywka, COO, Ph.D
Mary Tanner, Executive
Roland Oetker, Chairman
Andreas Pinkwart, Executive
Paul Herrling, Executive, Ph.D
Colin Bond, CFO, MBA
Cord Dohrmann, Executive
Iris LoewFriedrich, Executive, Ph.D
Bernd Hirsch, Executive
Enno Spillner, CFO
Elaine Sullivan, Executive
Wolfgang Plischke, Chairman, Ph.D

Stock Performance Indicators

Did you try this?

Run Technical Analysis Now

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
All  Next Launch Technical Analysis

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Evotec AG and U S Bancorp. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.